Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Incyte, Syndax Team Up On Chronic GVHD, But Some Uncertainties Remain

Data Still Early For Drug In $600m Deal

Executive Summary

The deal could nevertheless give Incyte a competitive edge, especially with combination potential between its JAK inhibitors and Syndax’s axatilimab.

You may also be interested in...



Syndax Readies FDA Filing In Leukemia After Stopping Revumenib Trial Early For Efficacy

The AUGMENT-101 study showed a strong response rate among acute leukemia patients who historically have a poor prognosis.

Finance Watch: Public Biopharma Firms Take Advantage Of Relative Upswing

Public Company Edition: Prometheus brought in $500m from a follow-on offering after reporting positive mid-stage results for its TL1A inhibitor. Even Novavax, struggling to make money from its COVID-19 vaccine, raised cash in dual offerings, but its valuation dropped significantly afterward.

Kyowa Decision Spells End For Syndax’s Entinostat In Breast Cancer?

Japanese firm's decision to end development of entinostat in its licensed territories marks possibly final blow to development of the HDAC inhibitor in breast cancer. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC145135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel